Guggenheim initiated coverage of Edgewise Therapeutics (EWTX) with a Buy rating and $41 price target
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- RBC sees Makary interview as potentially positive for biotech stocks
- Edgewise Therapeutics: A Promising Future Amidst Initial Concerns
- Biotech Alert: Searches spiking for these stocks today
- Edgewise downgraded yesterday at Scotiabank after CIRRUS-HCM readout
- Edgewise downside move a buying opportunity, says RBC Capital